InseRT

Madison, WI · Medtech · Defunct

Real-time MRI-guided surgical platform for minimally invasive intracerebral hemorrhage treatment with drug delivery monitoring

Grants
$3.4M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Platform for MR-Guided Neurotherapeutic Drug Delivery$938,975
Federal grantDepartment of Health and Human Services · Phase II · Platform for MR-Guided Neurotherapeutic Drug Delivery$1,451,781
Federal grantDepartment of Health and Human Services · Phase II · Platform for MR-Guided Neurotherapeutic Drug Delivery$512,806
Federal grantDepartment of Health and Human Services · Phase I · Accelerated Minimally Invasive Brain Clot Evacuation Using Guided Drug Delivery$229,215
Federal grantDepartment of Health and Human Services · Phase I · Accelerated Minimally Invasive Brain Clot Evacuation Using Guided Drug Delivery$229,215
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2094Cognext Diagnostics LLC——
2095AURICLE HEALTH INC——
2096FOLI BIO INC.——
2097InseRT——
2098Monogram Orthopaedics Inc.——
2099GEL4MED, INC.——
2100EXVADE BIOSCIENCE INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.